Parisa Mashayekhi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Parisa Mashayekhi has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Mir Davood Omrani
Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran
8 shared publications Ali Dehghanifard
Molecular Medicine Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
3 shared publicationsMohammad Mehdi Jahani
Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 shared publications- Adnan Khosravi
Research Center of Thoracic Oncology (RCTO), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 shared publications - Ali Dehghanifard
Molecular Medicine Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
2 shared publications - Mohammad Mehdi Jahani
Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 shared publications
Latest Publications
- 1 November 2025
- Published by InkVista Publishing House
- Vol. 29 (6) , 405-412
Liquid Biopsy for EGFR Mutation Detection in NSCLC: Evaluation of Plasma ctDNA and Comparison with Plasma exoDNA
- 1 November 2025
- Published by InkVista Publishing House
- Vol. 29 (6) , 405-412
Liquid Biopsy for EGFR Mutation Detection in NSCLC: Evaluation of Plasma ctDNA and Comparison with Plasma exoDNA
- Open Access
- 1 November 2025
- Vol. 29 (6) , 405-412
Liquid Biopsy for EGFR Mutation Detection in NSCLC: Evaluation of Plasma ctDNA and Comparison with Plasma exoDNA.
Accurate detection of actionable EGFR mutations is essential for guiding targeted therapy in NSCLC. Liquid biopsy approaches using ctDNA and exoDNA offer noninvasive alternatives for molecular profiling. This study evaluated the diagnostic performance of nested PCR combined with sanger sequencing for detecting common EGFR mutations (exon 19 deletions and the L858R point mutation) in plasma samples from Iranian NSCLC patients. In this retrospective observational study, blood samples were collected from 30 NSCLC patients with confirmed EGFR mutations. ctDNA was extracted from plasma and analyzed using nested PCR followed by sanger sequencing. Specificity was assessed in 20 EGFR-wild type NSCLC patients serving as controls. Diagnostic performance was further evaluated in relation to clinicopathological factors. EGFR mutations were detected in plasma ctDNA in 63.3% of patients. Detection sensitivity was significantly associated with tumor stage but was independent of mutation subtype, age, sex, or smoking status. The assay showed high specificity, with no false positive results in control samples (95% CI: 83.9-100.0%). Although exoDNA analysis demonstrated a higher sensitivity than ctDNA (76.6% vs. 63.3%), this difference was not statistically significant. Notably, combined analysis of ctDNA and exoDNA increased overall detection sensitivity to 80%. Nested PCR with sanger sequencing represents a reliable rule in strategy for EGFR mutation detection in plasma. Integrating ctDNA and exoDNA analyses substantially improves sensitivity and may enhance noninvasive molecular diagnostics in NSCLC.
- 1 November 2025
- Vol. 29 (6) , 405-412
Open AccessLiquid Biopsy for EGFR Mutation Detection in NSCLC: Evaluation of Plasma ctDNA and Comparison with Plasma exoDNA.
Accurate detection of actionable EGFR mutations is essential for guiding targeted therapy in NSCLC. Liquid biopsy approaches using ctDNA and exoDNA offer noninvasive alternatives for molecular profiling. This study evaluated the diagnostic performance of nested PCR combined with sanger sequencing for detecting common EGFR mutations (exon 19 deletions and the L858R point mutation) in plasma samples from Iranian NSCLC patients. In this retrospective observational study, blood samples were collected from 30 NSCLC patients with confirmed EGFR mutations. ctDNA was extracted from plasma and analyzed using nested PCR followed by sanger sequencing. Specificity was assessed in 20 EGFR-wild type NSCLC patients serving as controls. Diagnostic performance was further evaluated in relation to clinicopathological factors. EGFR mutations were detected in plasma ctDNA in 63.3% of patients. Detection sensitivity was significantly associated with tumor stage but was independent of mutation subtype, age, sex, or smoking status. The assay showed high specificity, with no false positive results in control samples (95% CI: 83.9-100.0%). Although exoDNA analysis demonstrated a higher sensitivity than ctDNA (76.6% vs. 63.3%), this difference was not statistically significant. Notably, combined analysis of ctDNA and exoDNA increased overall detection sensitivity to 80%. Nested PCR with sanger sequencing represents a reliable rule in strategy for EGFR mutation detection in plasma. Integrating ctDNA and exoDNA analyses substantially improves sensitivity and may enhance noninvasive molecular diagnostics in NSCLC.
- Open Access
- 1 April 2025
- Published by Wolters Kluwer Health in Advanced Biomedical Research
- Vol. 14 (1) , 39
Review of Plasma Exosomal DNA for Detecting EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC)
This review systematically evaluated the literature on detecting epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) using plasma exosomal DNA by analyzing data from eight studies selected from a comprehensive literature search (PubMed, Embase, Web of Science; 2010–2024). The findings revealed a wide range of EGFR mutation prevalence (10%–26.8%) across studies, with most mutations located in exons 19 and 21. Comparative analysis highlighted the potential of plasma exosomal DNA (exDNA) as a non-invasive alternative to tissue biopsy, although significant heterogeneity in sensitivity and specificity was observed across liquid biopsy methods (including circulating tumor cells and exDNA analyses). This heterogeneity underscores the need for standardization and further validation to optimize the clinical utility of plasma exDNA in detecting EGFR mutations, monitoring treatment response, and identifying resistance mechanisms in NSCLC.
- 1 April 2025
- Published by Wolters Kluwer Health in Advanced Biomedical Research
- Vol. 14 (1) , 39
Open AccessReview of Plasma Exosomal DNA for Detecting EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC)
This review systematically evaluated the literature on detecting epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) using plasma exosomal DNA by analyzing data from eight studies selected from a comprehensive literature search (PubMed, Embase, Web of Science; 2010–2024). The findings revealed a wide range of EGFR mutation prevalence (10%–26.8%) across studies, with most mutations located in exons 19 and 21. Comparative analysis highlighted the potential of plasma exosomal DNA (exDNA) as a non-invasive alternative to tissue biopsy, although significant heterogeneity in sensitivity and specificity was observed across liquid biopsy methods (including circulating tumor cells and exDNA analyses). This heterogeneity underscores the need for standardization and further validation to optimize the clinical utility of plasma exDNA in detecting EGFR mutations, monitoring treatment response, and identifying resistance mechanisms in NSCLC.
- Open Access
- 11 March 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-14
Efficacy of liquid biopsy for genetic mutations determination in non-small cell lung cancer: a systematic review on literatures
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide and is often diagnosed at advanced stages, limiting treatment options. This systematic review aims to evaluate the efficacy of liquid biopsy in detecting genetic mutations in NSCLC, focusing on its sensitivity, specificity, clinical utility, and potential to guide personalized treatment strategies. A systematic search was conducted in PubMed, Scopus, Embase, Web of Science, and Cochrane Library to identify relevant studies published between 1990 and September 2024. Eligible studies included comparative analyses of liquid biopsy techniques for NSCLC diagnosis, prognosis, progression, or treatment response. This review adheres to the PRISMA 2020 guidelines and assesses study quality using the QUADAS framework. A total of 30 studies were included. Digital droplet PCR (ddPCR) demonstrated the highest sensitivity, detecting low-frequency mutations such as EGFR T790M at levels as low as 0.01%. Next-generation sequencing (NGS) provided comprehensive mutational profiling, revealing tumor heterogeneity and co-existing mutations but required high-quality plasma samples. The cobas EGFR Mutation Test, while less sensitive than ddPCR, remains widely used due to its clinical accessibility. Emerging methods, including extracellular vesicle analysis, show promise but require further validation. Additionally, liquid biopsy effectively identified non-EGFR mutations, such as KRAS, ALK, and MET amplifications, expanding its clinical applicability. Liquid biopsy is a transformative tool in NSCLC management, offering a minimally invasive approach for mutation detection, disease monitoring, and treatment guidance. Future research should focus on multicenter trials and emerging technologies to enhance clinical integration and broaden applicability across different cancer types.
- 11 March 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-14
Open AccessEfficacy of liquid biopsy for genetic mutations determination in non-small cell lung cancer: a systematic review on literatures
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide and is often diagnosed at advanced stages, limiting treatment options. This systematic review aims to evaluate the efficacy of liquid biopsy in detecting genetic mutations in NSCLC, focusing on its sensitivity, specificity, clinical utility, and potential to guide personalized treatment strategies. A systematic search was conducted in PubMed, Scopus, Embase, Web of Science, and Cochrane Library to identify relevant studies published between 1990 and September 2024. Eligible studies included comparative analyses of liquid biopsy techniques for NSCLC diagnosis, prognosis, progression, or treatment response. This review adheres to the PRISMA 2020 guidelines and assesses study quality using the QUADAS framework. A total of 30 studies were included. Digital droplet PCR (ddPCR) demonstrated the highest sensitivity, detecting low-frequency mutations such as EGFR T790M at levels as low as 0.01%. Next-generation sequencing (NGS) provided comprehensive mutational profiling, revealing tumor heterogeneity and co-existing mutations but required high-quality plasma samples. The cobas EGFR Mutation Test, while less sensitive than ddPCR, remains widely used due to its clinical accessibility. Emerging methods, including extracellular vesicle analysis, show promise but require further validation. Additionally, liquid biopsy effectively identified non-EGFR mutations, such as KRAS, ALK, and MET amplifications, expanding its clinical applicability. Liquid biopsy is a transformative tool in NSCLC management, offering a minimally invasive approach for mutation detection, disease monitoring, and treatment guidance. Future research should focus on multicenter trials and emerging technologies to enhance clinical integration and broaden applicability across different cancer types.
- Open Access
- 19 August 2024
- Published by Knowledge E DMCC in Iranian Journal of Public Health
- Vol. 53 (8) , 1864-1870
Investigating the Potential Impact of CCR5-Δ32 Variant on COVID-19 Outcome: A Case-Control Study in Iranian Population
Background: The impact of CCR5-Δ32 on COVID-19 outcomes has been the focus of much research. This genetic variant may protect against SARS-CoV-2 infection, while others have produced conflicting results. Given the controversial results of previous research on different populations, we aimed to investigate the possible association between the CCR5-Δ32 variant and COVID-19 severity in an Iranian population. Methods: This case-control study was conducted between 25th of April till 10th of October 2021 at Rasoul Akram Hospital of Iran University of Medical Sciences, Tehran, Iran. We investigated the association between CCR5-Δ32 genotype and COVID-19 severity in 200 unrelated Iranian patients. The patients were divided into 2 groups: 100 patients with severe COVID-19 (case group) and 100 patients with mild COVID-19 (control group). Genotyping of CCR5-Δ32 was performed using the polymerase chain reaction (PCR) technique. Results: The frequency of CCR5-Δ32 allele was 11 in the case group and 16 in the control group. However, no significant association was found between this genetic variant and the clinical outcomes of COVID-19. Conclusion: The CCR5-Δ32 variant cannot serve as a reliable predictive factor for identifying individuals prone to developing severe COVID-19 in Iranian population. Additionally, targeting CCR5 would not be a viable treatment approach for COVID-19 in Iranians.
- 19 August 2024
- Published by Knowledge E DMCC in Iranian Journal of Public Health
- Vol. 53 (8) , 1864-1870
Open AccessInvestigating the Potential Impact of CCR5-Δ32 Variant on COVID-19 Outcome: A Case-Control Study in Iranian Population
Background: The impact of CCR5-Δ32 on COVID-19 outcomes has been the focus of much research. This genetic variant may protect against SARS-CoV-2 infection, while others have produced conflicting results. Given the controversial results of previous research on different populations, we aimed to investigate the possible association between the CCR5-Δ32 variant and COVID-19 severity in an Iranian population. Methods: This case-control study was conducted between 25th of April till 10th of October 2021 at Rasoul Akram Hospital of Iran University of Medical Sciences, Tehran, Iran. We investigated the association between CCR5-Δ32 genotype and COVID-19 severity in 200 unrelated Iranian patients. The patients were divided into 2 groups: 100 patients with severe COVID-19 (case group) and 100 patients with mild COVID-19 (control group). Genotyping of CCR5-Δ32 was performed using the polymerase chain reaction (PCR) technique. Results: The frequency of CCR5-Δ32 allele was 11 in the case group and 16 in the control group. However, no significant association was found between this genetic variant and the clinical outcomes of COVID-19. Conclusion: The CCR5-Δ32 variant cannot serve as a reliable predictive factor for identifying individuals prone to developing severe COVID-19 in Iranian population. Additionally, targeting CCR5 would not be a viable treatment approach for COVID-19 in Iranians.
- Open Access
- 1 July 2024
- Published by Apex Publishing in Iranian Biomedical Journal
- Vol. 28 (4) , 206-213
Assessing the Sensitivity of Nested PCR Followed by Direct Sequencing on Exosomal DNA for EGFR Mutation Detection in NSCLC
Background: Early and minimally invasive detection of epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) patients is a promising tool to select patients for targeted therapy in order to improve their prognosis. This study aimed to identify a sensitive, cost-effective, and easily accessible noninvasive method for detecting the ...
- 1 July 2024
- Published by Apex Publishing in Iranian Biomedical Journal
- Vol. 28 (4) , 206-213
Open AccessAssessing the Sensitivity of Nested PCR Followed by Direct Sequencing on Exosomal DNA for EGFR Mutation Detection in NSCLC
Background: Early and minimally invasive detection of epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) patients is a promising tool to select patients for targeted therapy in order to improve their prognosis. This study aimed to identify a sensitive, cost-effective, and easily accessible noninvasive method for detecting the ...
- Open Access
- 26 September 2023
- Published by Springer Nature in Human Genome Variation
- Vol. 10 (1) , 1-3
A novel de novo canonical splice site mutation in the PTCH1 gene in a male patient with mild psychomotor retardation and autistic traits: a case report
Basal cell nevus syndrome (BCNS), or Gorlin syndrome, is a rare autosomal dominant disorder caused by mutations in the tumor suppressor gene PTCH1 with complete penetrance and variable expressivity characterized by a broad spectrum of developmental anomalies and a predisposition to neoplasms. Herein, we report a novel de novo splice site mutation in the PTCH1 gene related to mild developmental delay and autistic traits in a 4-year-old male patient.
- 26 September 2023
- Published by Springer Nature in Human Genome Variation
- Vol. 10 (1) , 1-3
Open AccessA novel de novo canonical splice site mutation in the PTCH1 gene in a male patient with mild psychomotor retardation and autistic traits: a case report
Basal cell nevus syndrome (BCNS), or Gorlin syndrome, is a rare autosomal dominant disorder caused by mutations in the tumor suppressor gene PTCH1 with complete penetrance and variable expressivity characterized by a broad spectrum of developmental anomalies and a predisposition to neoplasms. Herein, we report a novel de novo splice site mutation in the PTCH1 gene related to mild developmental delay and autistic traits in a 4-year-old male patient.
- Open Access
- 1 May 2023
- Published by Maad Rayan Publishing Company in International Journal of Infectious Diseases
- Vol. 26 (5) , 261-266
Influence of HLA-A, -B, -DR Polymorphisms on the Severity of COVID-19: A Case-Control Study in the Iranian Population
Background: As an emerging pandemic disease, COVID-19 encompasses a spectrum of clinical diagnoses, from the common cold to severe respiratory syndrome. Considering the shreds of evidence demonstrating the relationship between human leukocyte antigen (HLA) allele diversity and infectious disease susceptibility, this study was conducted to determine the association of HLA alleles with COVID-19 severity in Iranian subjects. Methods: In this case-control study, a total of 200 unrelated individuals (consisting of 100 people with severe COVID-19 and an average age of 55.54 as the case group, and 100 patients with mild COVID-19 with an average age of 48.97 as the control group) were recruited, and HLA typing (Locus A, B, and DR) was performed using the Olerup sequence-specific oligonucleotide (SSO) HLA-typing kit. Results: Our results showed that HLA-A*11 and HLA-DRB1*14 alleles were more frequently observed in severe COVID-19 cases, while HLA-B*52 was more common in mild cases, which was in agreement with some previous studies. Conclusion: Our results confirmed the evidence for the association of HLA alleles with COVID-19 outcomes. We found that HLA-A*11 and HLA-DRB1*14 alleles may be susceptibility factors for severe COVID-19, while HLA-B*52 may be a protective factor. These findings provide new insight into the pathogenesis of COVID-19 and help patient management.
- 1 May 2023
- Published by Maad Rayan Publishing Company in International Journal of Infectious Diseases
- Vol. 26 (5) , 261-266
Open AccessInfluence of HLA-A, -B, -DR Polymorphisms on the Severity of COVID-19: A Case-Control Study in the Iranian Population
Background: As an emerging pandemic disease, COVID-19 encompasses a spectrum of clinical diagnoses, from the common cold to severe respiratory syndrome. Considering the shreds of evidence demonstrating the relationship between human leukocyte antigen (HLA) allele diversity and infectious disease susceptibility, this study was conducted to determine the association of HLA alleles with COVID-19 severity in Iranian subjects. Methods: In this case-control study, a total of 200 unrelated individuals (consisting of 100 people with severe COVID-19 and an average age of 55.54 as the case group, and 100 patients with mild COVID-19 with an average age of 48.97 as the control group) were recruited, and HLA typing (Locus A, B, and DR) was performed using the Olerup sequence-specific oligonucleotide (SSO) HLA-typing kit. Results: Our results showed that HLA-A*11 and HLA-DRB1*14 alleles were more frequently observed in severe COVID-19 cases, while HLA-B*52 was more common in mild cases, which was in agreement with some previous studies. Conclusion: Our results confirmed the evidence for the association of HLA alleles with COVID-19 outcomes. We found that HLA-A*11 and HLA-DRB1*14 alleles may be susceptibility factors for severe COVID-19, while HLA-B*52 may be a protective factor. These findings provide new insight into the pathogenesis of COVID-19 and help patient management.